Knight Therapeutics Inc. (GUD) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning ladies and gentlemen, my name is Sergio and I will be your operator today. Welcome to Knight Therapeutics, second quarter 2025 results conference call. Before turning the call over to Samira Sakia, president and CEO of Knight, designers are reminded that portions of today's discussion may, by their nature, necessarily involve risk and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The company considers the assumptions on which these forward-looking statements are based to be reasonable, and they were prepared, but caches that these assumptions regarding the future events, many of which are beyond the control of the company and its subsidiaries, may ultimately prove to be incorrect. The company disclaims any intention or obligation to update or revise any forward-looking statements whether a result of the information, future events, except as required by law. We would also like to remind you, questions during today's call will be taken from Analyst Only. Should there be any further questions, please contact Knight's Investor Relations Department via email to IR at knightdx.com or via phone at -484-4483. I would like to remind everyone that this call is being recorded today, August 7th, 2025. And we'll now like to turn the meeting over to your host for today's call, Samira Sekia. Please go ahead, Ms. Sekia. Thank you, Sergio. Good morning, everyone, and welcome to Knight Therapeutics' second quarter 2025 conference call. I'm joined on today's call with Amal Khoury, our Chief Business Officer, and Arvind Uchena, our Chief Financial Officer. I'm excited to announce that for the first half of 2025, we achieved a record high adjusted revenues of $197 million driven by our innovative...